Missed a dose of semaglutide or tirzepatide?

Why the brand and formulation matter

In the 2026 US prescribing information, Ozempic injection measures its single-missed-dose window from the missed dose; Zepbound injection uses a different window. Wegovy injection instead describes the time remaining until the next scheduled dose. The same Wegovy label has separate instructions for tablets. These examples are US product records, not interchangeable directions for another country, brand or compounded product. Check the leaflet supplied with your medicine and contact your pharmacist if the timing or product is unclear.123

What if more than one dose was missed?

Do not assume that the rule for a single missed dose applies after a longer interruption. The 2026 US Wegovy injection label says that, after two or more consecutive missed doses, restarting the dose-escalation schedule may sometimes be considered to reduce gastrointestinal side effects; the decision depends on the person and treatment. UK NHS guidance advises contacting a doctor if more than one semaglutide injection is missed. Ask your prescribing team how to restart the exact product rather than choosing a dose yourself. Explore what happens after stopping and how to read the withdrawal trials.24

What if I cannot remember or took too much?

Do not take an extra dose to make up for an uncertain one. Contact a pharmacist, prescriber or appropriate urgent advice service with the product name, strength, last confirmed dose and what may have happened. NHS advises seeking medical advice for excess semaglutide because it can be dangerous. Seek urgent help for severe or concerning symptoms; see abdominal symptoms that need assessment.4

Why can compounded vials be confusing?

In the United States, the FDA has reported dosing errors involving compounded injectable semaglutide, including cases requiring hospital care. Some errors involved measuring liquid from a vial or confusing milligrams, millilitres and syringe markings; some were prescribing or calculation errors. Products can have different concentrations, and instructions intended for one vial or syringe may not apply to another. These reports cannot tell us how often errors occur or whether every reported harm was caused by the medicine.

If the label, concentration, syringe or directions are unclear, contact the dispensing pharmacist, compounder or prescriber before taking the product. Do not use an online conversion or another person’s instructions. If you may have taken too much, promptly contact a poison information service or urgent medical service, even if symptoms have not yet appeared; seek emergency help for severe symptoms. Keep the container and instructions available for the care team. Rules and available services vary by country; see semaglutide products and quality and product-specific storage.

One FDA-described report illustrates the problem: after difficulty clarifying the prescribed instructions, a person searched online and took five times the intended amount. This is one report, not a rate or a typical outcome, and it does not tell us what another vial contains. A measurement in millilitres describes liquid volume; milligrams describe the amount of medicine, and syringe markings must be interpreted with the particular concentration and device. Ask the dispensing professional to explain the written directions for that exact vial and syringe.5

What if diabetes medicines are involved?

A missed dose may affect blood glucose, and the right advice depends on the full treatment plan, including any insulin or other diabetes medicines. Do not stop or adjust another prescribed medicine based on this guide. Contact the clinician or diabetes team responsible for your care, especially when you are unwell or have missed several doses. For the broader evidence and product distinctions, see semaglutide and tirzepatide.

Low blood sugar is more likely when semaglutide is used with certain other diabetes medicines. Shaking, sweating, dizziness or confusion can be warning signs, though they can have other causes. If you have diabetes and suspect low blood sugar, check your glucose if you can and act promptly using your diabetes team’s hypo plan. If you are awake and can swallow safely, the NHS advises a fast-acting sugary drink or glucose, then checking again after 10–15 minutes and repeating the fast-acting sugar if it is still low. Once it has recovered, follow your plan for a longer-lasting snack or your next meal. If someone is unconscious or cannot swallow safely, call emergency services and do not give food or drink by mouth.46